OBJECTIVES: After completing this course, learners will be able to: 1)Understand current unmet needs in Myasthenia Gravis (MG) treatment, 2) describe the major new treatment approaches for MG, 3) explain key considerations for complement inhibitor therapy, 4) compare benefits and limitations of different treatment options 5) apply current guidelines for medication tapering.

ACCREDITATION STATEMENT: The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The AANEM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AANEM also designates this enduring material for a maximum of  0.5 CEU credits.


DISCLOSURE INFORMATION: The presenters had no relevant conflicts to disclose.

Content from this presentation is not to be used without express written permission of the AANEM and the presenters involved in the presentation.